GlassScriptPhysician profile
Robert James Allen
NPI 1750543542
$876.48
in general payments reported to CMS, 2019-2025
11 companies · $463 in 2025
The $463 reported for 2025 was more than what 77% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.41 · 2020: $259 · 2021: $108 · 2023: $22.14 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $350.24 | 2020-2023 | Eterna |
| Globus Medical, INC. | $143.48 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $66.86 | 2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.69 | 2025 | Relistor |
| Scilex Pharmaceuticals INC. | $59.64 | 2025 | |
| Indivior INC. | $42.01 | 2025 | Sublocade |
| Boston Scientific Corporation | $40.05 | 2019-2020 | |
| Valinor Pharma, LLC | $38.98 | 2025 | Movantik |
| Vertex Pharmaceuticals Incorporated | $28.39 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.69 | 2021 | |
| Alkermes, INC. | $17.45 | 2025 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.